Oncopeptides AB ONCO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ONCO is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- SEK 2.92
- Day Range
- SEK 2.89–3.01
- 52-Week Range
- SEK 2.80–8.30
- Bid/Ask
- SEK 2.89 / SEK 2.91
- Market Cap
- SEK 366.76 Mil
- Volume/Avg
- 232,672 / 885,446
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 10.50
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Oncopeptides AB is a biotech company focused on the research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Conjugate (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It has focused on the development of the product candidate Melflufen (Pepaxti), a peptide-conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Compounds. Melflufen is intended as an effective treatment for hematological cancers and in particular multiple myeloma.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 67
- Website
- https://www.oncopeptides.com
Comparables
Valuation
|
Metric
|
ONCO
|
CRBU
|
APLM
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 6.52 | 0.89 | 2.04 |
Price/Sales | 10.50 | 7.90 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ONCO
|
CRBU
|
APLM
|
|---|---|---|---|
Quick Ratio | 6.63 | 11.75 | 2.82 |
Current Ratio | 6.68 | 11.97 | 2.95 |
Interest Coverage | — | — | −1,154.63 |
Quick Ratio
ONCO
CRBU
APLM
Profitability
|
Metric
|
ONCO
|
CRBU
|
APLM
|
|---|---|---|---|
Return on Assets (Normalized) | −70.80% | −23.27% | −123.31% |
Return on Equity (Normalized) | −106.72% | −28.24% | — |
Return on Invested Capital (Normalized) | −90.80% | −26.03% | — |
Return on Assets
ONCO
CRBU
APLM
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Wdrvszht | Dhsph | $559.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Mgnflhk | Ngjpfyf | $103.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Rvdhtnz | Lxxhng | $103.3 Bil | |
MRNA
| Moderna Inc | Lxfksjt | Zfmd | $42.7 Bil | |
ARGX
| argenx SE ADR | Ctsppsc | Qfwh | $23.1 Bil | |
BNTX
| BioNTech SE ADR | Dfzcfdn | Gpvnm | $21.7 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ssfmgdb | Cwltt | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Kgjrcsdx | Hkccb | $15.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Zmyjlvpny | Jgtkyt | $12.7 Bil | |
INCY
| Incyte Corp | Tlklghb | Yqhbms | $11.9 Bil |